BCRX  Biocryst Pharmaceuticals Inc.




Health Care


Biotechnology: Biological Products (No Diagnostic Substances)

Market Cap.


Vuru Grade


Current Price

+0.10 (+3.36%)

Company Metrics

  • P/E 0
  • P/S 4.75
  • P/B 7.90
  • EPS -0.69
  • Cash ROIC -251.78%
  • Cash Ratio 0.80
  • Dividend 0 / N/A %
  • Avg. Vol. 723,725.00
  • Shares 73.69M
  • Market Cap. 226.97M

Company Description

BioCryst Pharmaceuticals, Inc. designs, optimizes, and develops small-molecule pharmaceuticals that block key enzymes involved in infectious diseases, cancer, and inflammatory diseases. It uses structure-based drug design, which incorporates multiple scientific disciplines, including biology, crystallography, medicinal chemistry, and computer modeling to develop new therapeutic candidates. The com... more

Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow


BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Current Analyst Ratings
Fiscal Standard - Jul 21, 2016
02/09/2016 - BioCryst Pharmaceuticals, Inc. was downgraded to “neutral” by analysts at JP Morgan. They now have a USD 5 price target on the stock.
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Fundamental Star Rating Report
CML News - Jul 12, 2016
This is a fundamental star rating report for BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) . The Capital Market Laboratories Star Rating is an objective, quantifiable measure of a company's operating and financial condition.
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Annual EBIT At $-39.444 Millions - Enterprise Leader
BioCryst Pharmaceuticals Inc. (BCRX) Drops 5.21% on July 13
Equities.com - Jul 14, 2016
BioCryst Pharmaceuticals Inc. (BCRX) was one of the Russell 2000's biggest losers for Wednesday July 13 as the stock slid 5.21% to $2.91, a loss of $-0.16 per share.
Look out the Analyst's PT Opinions: AGCO Corporation (NYSE:AGCO) , BioCryst ...
Is stories - 14 hours ago
AGCO Corporation (NYSE:AGCO) negotiated 760.39 thousand shares against it an average volume of 914.32 thousand shares. The stock concluded the recent trade at $48.55 with downbeat trend move of -1.54%.
Stock Up Nicely This Week: BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)
TGP - 10 hours ago
Investors BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) are heading into the weekend on a positive note as the stock provided some gains this week moving 4.05% over the past 5 trading days.
HC Wainwright Maintains Buy On BioCryst Pharmaceuticals, Inc. (BCRX) Following ...
Smarter Analyst - May 6, 2016
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) shares slipped yesterday 9% after the drug discovery company reported first-quarter results and update on its clinical progress.
New Roundup- Medivation (NASDAQ:MDVN), St. Jude Medical (NYSE:STJ), BioCryst ... - Seneca Globe
Stock Update (NASDAQ:BCRX): BioCryst Pharmaceuticals, Inc. Announces Clinical ...
Smarter Analyst - Feb 8, 2016
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced results from OPuS-2 (Oral ProphylaxiS-2), a clinical trial of avoralstat administered three times daily as a liquid-filled soft gel formulation for the prophylactic treatment of hereditary ...
Is BioCryst Reaching Crush Depth? - 24/7 Wall St.
BioCryst Pharmaceuticals, Inc Crashes on Failure of OPuS 2 Clinical Trial for HAE - Bidness ETC
BioCryst Pharmaceuticals, Inc. versus Eagle Pharmaceuticals Inc. Head to Head ...
CML News - Jul 6, 2016
Eagle Pharmaceuticals Inc. has a higher fundamental rating then BioCryst Pharmaceuticals, Inc. which has an impact on the head-to-head comparison.
BioCryst Pharmaceuticals Inc. (BCRX) Earns "Buy" Rating from FBR & Co - Community Financial News
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Median Sales Estimate At $4.974 - Equities Focus
Here's Why Shares of BioCryst Pharmaceuticals, Inc. Are Falling Today
Motley Fool - Oct 8, 2015
What: Shares of BioCryst Pharmaceuticals (NASDAQ:BCRX), a biotech company that specializes in the development of small molecular drugs, sank by over 20% today on heavy volume.
BioCryst Pharmaceuticals (BCRX) Stock Drops Despite Positive Drug Trial Results - TheStreet.com
BioCryst Announces Successful Phase 1 Clinical Trial of BCX7353 - GlobeNewswire (press release)
BioCryst Pharmaceuticals Inc Stock Momentum Hits Extreme Weakness
CML News - Jul 14, 2016
This is a momentum stock rating analysis for BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) . The company has a one bull momentum rating which indicates extreme weakness.